Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).
Factors that predict nonresponse to drug therapy (brofaromine or fluvoxamine) were investigated in a sample of 44 panic disorder patients. We used a strict definition of nonresponse to find patients who did not respond at all after 12 weeks of treatment. Using this definition, 15 patients (32.6%) were considered nonresponders. Nonresponders had a higher score on the Blood-Injury subscore of the Fear Questionnaire (FQ) and more often had high scores on several FQ subscores, indicative of comorbid phobic symptoms. These variables were subsequently used to predict nonresponse.
Slaap
B R
BR
Department of Psychiatry, Rudolf Magnus Institute for Neuroscience, Academic Hospital Utrecht, The Netherlands.
van Vliet
I M
IM
Westenberg
H G
HG
den Boer
J A
JA
D000328:Adult; D000379:Agoraphobia / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D010200:Panic / Q000187:drug effects; D016584:Panic Disorder / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010555:Personality Inventory; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D010880:Piperidines / Q000008:administration & dosage*; D011379:Prognosis; D016896:Treatment Outcome
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; C038213:brofaromine; D016666:Fluvoxamine